MedTrace Logo

Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19

NCT04568018 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-07-21

No results posted yet for this study

Summary

The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.

Conditions

  • ARDS Due to COVID-19

Interventions

DRUG

Surfactant

Inhalation of surfactant emulsion at 150 mg

Sponsors & Collaborators

  • Biosurf LLC.

    lead INDUSTRY

Principal Investigators

  • Sergey Avdeev, D.M.S. · FSAEI of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University)

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-03
Primary Completion
2021-10-31
Completion
2021-12-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04568018 on ClinicalTrials.gov